Decision ruleHaematology
Nordic model for erythropoietin ± G-CSF response in MDS
Predicts the probability of erythroid response to erythropoietin plus G-CSF in the anaemia of myelodysplastic syndromes.
Updated 30 October 2026
When to use it
Lower-risk MDS with symptomatic anaemia, before starting an erythropoiesis-stimulating agent.
What it needs
- Serum EPO
- Red cell transfusion need
The points for each answer and the automatic total are in the app.
How to interpret it
| Result | Interpretation |
|---|---|
| ≤ 0 | High probability of response (≈ 61 % in validation) |
| 1 | Intermediate probability of response (≈ 14 % in validation) |
| ≥ 2 | Low probability of response: treatment not recommended |
Practical tip
The two predictors are serum EPO (> 500 U/L) and transfusion need (≥ 2 red cell units per month).
3 more practical tips in the app.
Reference
A support tool for healthcare professionals: it guides and does not replace clinical judgement.
